Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBITDA Margin (2020 - 2026)

Bioventus filings provide 6 years of EBITDA Margin readings, the most recent being 12.28% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 2214.0% to 12.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.85%, a 1529.0% increase, with the full-year FY2025 number at 4.95%, up 1388.0% from a year prior.
  • EBITDA Margin hit 12.28% in Q4 2025 for Bioventus, up from 1.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 29.08% in Q2 2021 to a low of 116.44% in Q2 2023.
  • Median EBITDA Margin over the past 5 years was 3.94% (2021), compared with a mean of 14.44%.
  • Biggest five-year swings in EBITDA Margin: crashed -10357bps in 2023 and later skyrocketed 11230bps in 2024.
  • Bioventus' EBITDA Margin stood at 1.48% in 2021, then tumbled by -3992bps to 60.43% in 2022, then surged by 45bps to 33.13% in 2023, then surged by 70bps to 9.86% in 2024, then soared by 225bps to 12.28% in 2025.
  • The last three reported values for EBITDA Margin were 12.28% (Q4 2025), 1.51% (Q3 2025), and 5.92% (Q2 2025) per Business Quant data.